-
Anti cold drugs are popular in the pharmaceutical industry
Time of Update: 2018-01-22
Market analysis of China Pharmaceutical network 】For the current hot sale of anti cold drugs and the phenomenon that many enterprises follow the trend in the investor interaction platform, a securitie
-
In cold weather, the "four types of drugs" are hot, and chain pharmacies are expected to continue to improve in the fourth quarter
Time of Update: 2022-11-25
The three chain heads of Da Shenlin, Laomin and Yifeng Pharmacy increased their revenue and profits in the first three quarters, achieving revenue of 14.
The three chain heads of Da Shenlin, Laomin and Yifeng Pharmacy increased their revenue and profits in the first three quarters, achieving revenue of 14.
-
The State Food and Drug Administration approved the marketing of cold and wet granules
Time of Update: 2022-10-25
js?cdnversion='+~(-new Date()/36e5)]; Recently, the State Medical Products Administration approved the marketing of Class 3.
js?cdnversion='+~(-new Date()/36e5)]; Recently, the State Medical Products Administration approved the marketing of Class 3.
js?cdnversion='+~(-new Date()/36e5)]; Recently, the State Medical Products Administration approved the marketing of Class 3.
-
Ten years of drinking ice, the blood is not cold: The new drug Gantenerumab for Alzheimer's disease is beginning to shine
Time of Update: 2022-09-21
*For medical professionals onlyFrom July 31 to August 4, 2022, the annual Alzheimer's Association International Conference (AAIC-2022) was successfully held in San Diego, USA. Advances in the developm
-
In-depth report| innovative drugs are cold in the world, and biotechnology companies are facing financing difficulties!
Time of Update: 2022-09-09
Measures for listed biotech companies facing financing difficulties According to Torreya Capital investment banking data, nearly 200 listed biotech companies around the world are trading below the value of their cash reserves, and as the shortage of funds in the public market increases, more and more biotech companies have to accept harsh trading conditions in order to survive.
-
Undercurrents are surging under the cold wave of medicine, how can investors and entrepreneurs "renew the life" of innovative drugs?
Time of Update: 2022-08-19
Deep Blue View: Founder: At present, the homogenization of innovative drugs is relatively serious, and the price of innovative drugs has generally dropped significantly after being included in medical insurance through "national talks".
-
Innovative drug investment in the cold winter: finding certainty from uncertainty
Time of Update: 2022-08-15
Return to the simplest logic of innovative drugsReturn to the simplest logic of innovative drugs At this point, I am afraid that the first-tier investors will complain: I don’t want to invest in those new topics, I really want to invest in small molecules and large molecules with higher certainty, but the low-risk targets are too strong, and the ones that are not.
-
THER ADV GASTROENTER: Perioperative safety analysis of antithrombotic drugs in patients with colorectal polyps undergoing cold snare resection
Time of Update: 2022-04-21
Compared to thermal snare polypectomy (HSP), CSP requires more superficial dissection but less damage to submucosal arteries than HSP, thereby minimizing adverse events such as perforation and delayed bleeding Guideline ThrombosisTo complete the study, researchers searched PubMed, Embase and Cochrane databases up to June 2021 .
-
of Drugs including Cold and Clearing Heat Preparations (No. 88 of 2021)
Time of Update: 2021-11-14
According to the evaluation results of adverse drug reactions, in order to further ensure the safety of the public use of drugs, the National Medical Products Administration has decided to make unified revisions to the four instructions of the cold and heat-clearing preparations [Adverse Reactions], [Contraindications] and [Precautions] .
-
The State Food and Drug Administration revised the instructions for 4 kinds of medicines including cold-removing preparations
Time of Update: 2021-08-08
According to the announcement, according to the results of the adverse drug reaction evaluation, in order to further protect the safety of the public use of drugs, the National Medical Products Administration has decided to uniformly revise the four instructions [adverse reactions], [taboos] and [precautions] items including cold-removing preparations .
-
Children cannot "feed" cold medicines randomly, 14 kinds of medicines for children were named by the Drug Administration
Time of Update: 2021-07-08
Reporter | Yuan YimingEdit | Xie Xin On April 23, the official website of the State Food and Drug Administration announced the "Announcement on Revising the Drug Inserts of 14 Varieties of Paracetamol and Mami Oral Solution" (hereinafter referred to as the "Announcement"), restricting and warning on the use of several cold medicines for children .
-
A batch of drugs suspended from sale recall related to cold heat particles, anti-sinusitis agent ...
Time of Update: 2021-02-11
On February 1st, the Hunan Provincial Drug Administration issued the Notice on 30 Batches of Drugs That Do Not Meet the Standards (No. 2 of 2021) (hereinafter referred to as the Notice).
-
15 drug suspension recalls: aspirin intestinal tablets, cold and hot particles...
Time of Update: 2021-01-13
verification confirmed that the current period of supervision and sampling found that 15 varieties of 18 batches do not meet the standard provisions, non-compliance with the provisions of the items including characteristics, inspection, content determination and so on.
-
Agios leukemia drug Tibsovo has been approved in the United States for its cold adaptation in Europe
Time of Update: 2020-10-31
Notably, in December, Idhifa, an IDH inhibitor at BMS, also withdrew its application for a new drug in the European market, having previously been approved by the FDA to treat AML for IDH2 mutations, and Idhifa failed to show in Phase 3 trials that drug therapy can extend a patient's life .
-
Agios leukemia drug Tibsovo has been approved in the United States for its cold adaptation in Europe.
Time of Update: 2020-10-28
it's worth noting that in December, Idhifa, an IDH inhibitor of BMS, also withdrew its application for a new drug in the European market, which had previously been approved by the FDA to treat AML for IDH2 mutations, and that Idhifa failed to show in Phase 3 trials that drug therapy can extend a patient's life.